• +1-646-491-9876
    • +91-20-67278686

    Search

    Parkinson's Disease Pipeline Review H1 2017

    Parkinson's Disease Pipeline Review H1 2017

    • Report Code ID: RW0001866819
    • Category Pharmaceuticals
    • No. of Pages 803
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Parkinson's Disease - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

    Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson's disease. Parkinson's disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 32, 41, 5, 180, 48 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 1, 46, 14 and 1 molecules, respectively.

    Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 8
    Parkinson's Disease - Overview 9
    Parkinson's Disease - Therapeutics Development 10
    Parkinson's Disease - Therapeutics Assessment 50
    Parkinson's Disease - Companies Involved in Therapeutics Development 70
    Parkinson's Disease - Drug Profiles 154
    Parkinson's Disease - Dormant Projects 737
    Parkinson's Disease - Discontinued Products 751
    Parkinson's Disease - Product Development Milestones 753
    Appendix 765

    List of Tables

    Number of Products under Development for Parkinson's Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..14) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..15) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..16) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H1 2017
    Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H1 2017
    Parkinson's Disease - Pipeline by AbbVie Inc, H1 2017
    Parkinson's Disease - Pipeline by AC Immune SA, H1 2017
    Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H1 2017
    Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H1 2017
    Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2017
    Parkinson's Disease - Pipeline by Amabiotics SAS, H1 2017
    Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
    Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H1 2017
    Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H1 2017
    Parkinson's Disease - Pipeline by Angita BV, H1 2017
    Parkinson's Disease - Pipeline by Antoxis Ltd, H1 2017
    Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
    Parkinson's Disease - Pipeline by APeT Holding BV, H1 2017
    Parkinson's Disease - Pipeline by ApoPharma Inc, H1 2017
    Parkinson's Disease - Pipeline by Aposense Ltd, H1 2017
    Parkinson's Disease - Pipeline by Araclon Biotech SL, H1 2017
    Parkinson's Disease - Pipeline by ArmaGen Inc, H1 2017
    Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
    Parkinson's Disease - Pipeline by Asceneuron SA, H1 2017
    Parkinson's Disease - Pipeline by AstraZeneca Plc, H1 2017
    Parkinson's Disease - Pipeline by Berg LLC, H1 2017
    Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H1 2017
    Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H1 2017
    Parkinson's Disease - Pipeline by BioArctic AB, H1 2017
    Parkinson's Disease - Pipeline by Biogen Inc, H1 2017
    Parkinson's Disease - Pipeline by BioHealthonomics Inc, H1 2017
    Parkinson's Disease - Pipeline by Biopharm GmbH, H1 2017
    Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Cardax Inc, H1 2017
    Parkinson's Disease - Pipeline by Carna Biosciences Inc, H1 2017
    Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
    Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2017
    Parkinson's Disease - Pipeline by Clera Inc, H1 2017
    Parkinson's Disease - Pipeline by Clevexel Pharma SAS, H1 2017
    Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Corium International Inc, H1 2017
    Parkinson's Disease - Pipeline by Curemark LLC, H1 2017
    Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Easywell Biomedical Inc , H1 2017
    Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Eli Lilly and Company, H1 2017
    Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H1 2017
    Parkinson's Disease - Pipeline by Evotec AG, H1 2017
    Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Forma Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by FPRT Bio Inc, H1 2017
    Parkinson's Disease - Pipeline by Genecode AS, H1 2017
    Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
    Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Parkinson's Disease - Pipeline by GenKyoTex SA, H1 2017
    Parkinson's Disease - Pipeline by Genmab A/S, H1 2017
    Parkinson's Disease - Pipeline by Genzyme Corp, H1 2017
    Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2017
    Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Parkinson's Disease - Pipeline by Herantis Pharma Plc, H1 2017
    Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
    Parkinson's Disease - Pipeline by HitGen LTD, H1 2017
    Parkinson's Disease - Pipeline by Huons Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by ICB International Inc, H1 2017
    Parkinson's Disease - Pipeline by Immungenetics AG, H1 2017
    Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H1 2017
    Parkinson's Disease - Pipeline by InnoMedica Holding AG, H1 2017
    Parkinson's Disease - Pipeline by Intec Pharma ltd, H1 2017
    Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2017
    Parkinson's Disease - Pipeline by International Stem Cell Corp, H1 2017
    Parkinson's Disease - Pipeline by Io Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Kainos Medicine Inc, H1 2017
    Parkinson's Disease - Pipeline by Khondrion BV, H1 2017
    Parkinson's Disease - Pipeline by KineMed Inc, H1 2017
    Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2017
    Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H1 2017
    Parkinson's Disease - Pipeline by Longevity Biotech Inc, H1 2017
    Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H1 2017
    Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2017
    Parkinson's Disease - Pipeline by M's Science Corp, H1 2017
    Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H1 2017
    Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H1 2017
    Parkinson's Disease - Pipeline by MedImmune LLC, H1 2017
    Parkinson's Disease - Pipeline by Merck & Co Inc, H1 2017
    Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017
    Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H1 2017
    Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H1 2017
    Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Montisera Ltd, H1 2017
    Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H1 2017
    Parkinson's Disease - Pipeline by Neonc Technologies Inc, H1 2017
    Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H1 2017
    Parkinson's Disease - Pipeline by Neuralstem Inc, H1 2017
    Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
    Parkinson's Disease - Pipeline by NeuroDerm Ltd, H1 2017
    Parkinson's Disease - Pipeline by NeuroNascent Inc, H1 2017
    Parkinson's Disease - Pipeline by NeurOp Inc, H1 2017
    Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H1 2017
    Parkinson's Disease - Pipeline by New World Laboratories Inc, H1 2017
    Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H1 2017
    Parkinson's Disease - Pipeline by nLife Therapeutics SL, H1 2017
    Parkinson's Disease - Pipeline by Novartis AG, H1 2017
    Parkinson's Disease - Pipeline by Novo Nordisk A/S, H1 2017
    Parkinson's Disease - Pipeline by NsGene A/S (Inactive) , H1 2017
    Parkinson's Disease - Pipeline by Omeros Corp, H1 2017
    Parkinson's Disease - Pipeline by Oncodesign SA, H1 2017
    Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by OPKO Health Inc, H1 2017
    Parkinson's Disease - Pipeline by Origenis GmbH, H1 2017
    Parkinson's Disease - Pipeline by Orion Oyj, H1 2017
    Parkinson's Disease - Pipeline by Oryzon Genomics SA, H1 2017
    Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H1 2017
    Parkinson's Disease - Pipeline by ParkCell AB, H1 2017
    Parkinson's Disease - Pipeline by Parkure Ltd, H1 2017
    Parkinson's Disease - Pipeline by Peptron Inc, H1 2017
    Parkinson's Disease - Pipeline by Pfizer Inc, H1 2017
    Parkinson's Disease - Pipeline by Pharma Two B Ltd, H1 2017
    Parkinson's Disease - Pipeline by Pharmaxis Ltd, H1 2017
    Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Pharnext SA, H1 2017
    Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H1 2017
    Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H1 2017
    Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H1 2017
    Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Promius Pharma LLC, H1 2017
    Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Prothena Corp Plc, H1 2017
    Parkinson's Disease - Pipeline by reMYND NV, H1 2017
    Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by SanBio Inc, H1 2017
    Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Saniona AB, H1 2017
    Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Shire Plc, H1 2017
    Parkinson's Disease - Pipeline by Sigma-Tau SpA, H1 2017
    Parkinson's Disease - Pipeline by SignPath Pharma Inc, H1 2017
    Parkinson's Disease - Pipeline by Signum Biosciences Inc, H1 2017
    Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by STATegics Inc, H1 2017
    Parkinson's Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Synthonics Inc, H1 2017
    Parkinson's Disease - Pipeline by Takara Bio Inc, H1 2017
    Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2017
    Parkinson's Disease - Pipeline by TechnoPhage SA, H1 2017
    Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H1 2017
    Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H1 2017
    Parkinson's Disease - Pipeline by Trevena Inc, H1 2017
    Parkinson's Disease - Pipeline by UCB SA, H1 2017
    Parkinson's Disease - Pipeline by UniQure NV, H1 2017
    Parkinson's Disease - Pipeline by Varinel Inc, H1 2017
    Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
    Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H1 2017
    Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Parkinson's Disease - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Parkinson's Disease - Discontinued Products, H1 2017
    Parkinson's Disease - Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Parkinson's Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    2-BBB Medicines BV
    4P Therapeutics LLC
    AbbVie Inc
    AC Immune SA
    Acorda Therapeutics Inc
    Adamas Pharmaceuticals Inc
    Addex Therapeutics Ltd
    Advinus Therapeutics Ltd
    Aeolus Pharmaceuticals Inc
    AFFiRiS AG
    Amabiotics SAS
    Amarantus Bioscience Holdings Inc
    American Gene Technologies International Inc
    Anavex Life Sciences Corp
    Angita BV
    Antoxis Ltd
    Aoxing Pharmaceutical Company Inc
    APeT Holding BV
    ApoPharma Inc
    Aposense Ltd
    Araclon Biotech SL
    ArmaGen Inc
    Arrien Pharmaceuticals LLC
    Asceneuron SA
    AstraZeneca Plc
    Berg LLC
    Bial - Portela & Ca SA
    Bio-Modeling Systems SAS
    BioArctic AB
    Biogen Inc
    BioHealthonomics Inc
    Biopharm GmbH
    BrainStorm Cell Therapeutics Inc
    Cantabio Pharmaceuticals Inc
    Cardax Inc
    Carna Biosciences Inc
    Cell Cure Neurosciences Ltd
    CHA Bio & Diostech Co Ltd
    Chipscreen Biosciences Ltd
    Clera Inc
    Clevexel Pharma SAS
    ContraVir Pharmaceuticals Inc
    Corium International Inc
    Curemark LLC
    Daewoong Pharmaceutical Co Ltd
    Denali Therapeutics Inc
    Easywell Biomedical Inc
    Edison Pharmaceuticals Inc
    Eli Lilly and Company
    Ensemble Therapeutics Corp
    Evotec AG
    Fabre-Kramer Pharmaceuticals Inc
    Forma Therapeutics Inc
    FPRT Bio Inc
    Genecode AS
    Generon (Shanghai) Corp Ltd
    Genervon Biopharmaceuticals LLC
    GenKyoTex SA
    Genmab A/S
    Genzyme Corp
    H. Lundbeck A/S
    Heptares Therapeutics Ltd
    Herantis Pharma Plc
    Hisamitsu Pharmaceutical Co Inc
    HitGen LTD
    Huons Co Ltd
    ICB International Inc
    Immungenetics AG
    Impel NeuroPharma Inc
    InnoMedica Holding AG
    Intec Pharma ltd
    InterMed Discovery GmbH
    International Stem Cell Corp
    Io Therapeutics Inc
    Jeil Pharmaceutical Co Ltd
    Kainos Medicine Inc
    Khondrion BV
    KineMed Inc
    Kissei Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    Lead Discovery Center GmbH
    Living Cell Technologies Ltd
    Longevity Biotech Inc
    Luye Pharma Group Ltd
    M et P Pharma AG
    M's Science Corp
    M3 Biotechnology Inc
    MedGenesis Therapeutix Inc
    MedImmune LLC
    Merck & Co Inc
    Metabolic Solutions Development Company LLC
    Minerva Neurosciences Inc
    Mission Therapeutics Ltd
    Mitochon Pharmaceuticals Inc
    Montisera Ltd
    Motac Neuroscience Ltd
    Neonc Technologies Inc
    Netherlands Translational Research Center BV
    Neuralstem Inc
    Neuraltus Pharmaceuticals Inc
    Neuren Pharmaceuticals Ltd
    NeuroDerm Ltd
    NeuroNascent Inc
    NeurOp Inc
    Neuropore Therapies Inc
    New World Laboratories Inc
    Newron Pharmaceuticals SpA
    nLife Therapeutics SL
    Novartis AG
    Novo Nordisk A/S
    NsGene A/S (Inactive)
    Omeros Corp
    Oncodesign SA
    Ono Pharmaceutical Co Ltd
    OPKO Health Inc
    Origenis GmbH
    Orion Oyj
    Oryzon Genomics SA
    Oxford BioMedica Plc
    ParkCell AB
    Parkure Ltd
    Peptron Inc
    Pfizer Inc
    Pharma Two B Ltd
    Pharmaxis Ltd
    Pharmicell Co Ltd
    Pharnext SA
    Phenomenome Discoveries Inc
    Plex Pharmaceuticals Inc
    Prana Biotechnology Ltd
    Prexton Therapeutics SA
    Promentis Pharmaceuticals Inc
    Promius Pharma LLC
    Proteostasis Therapeutics Inc
    Prothena Corp Plc
    reMYND NV
    Sage Therapeutics Inc
    SanBio Inc
    Saneron CCEL Therapeutics Inc
    Saniona AB
    Serina Therapeutics Inc
    Shire Plc
    Sigma-Tau SpA
    SignPath Pharma Inc
    Signum Biosciences Inc
    SK Biopharmaceuticals Co Ltd
    STATegics Inc
    Stealth BioTherapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Sun Pharma Advanced Research Company Ltd
    Sunovion Pharmaceuticals Inc
    Synthonics Inc
    Takara Bio Inc
    TauRx Therapeutics Ltd
    TechnoPhage SA
    Teikoku Pharma USA Inc
    Teva Pharmaceutical Industries Ltd
    Titan Pharmaceuticals Inc
    Trevena Inc
    UCB SA
    UniQure NV
    Varinel Inc
    VistaGen Therapeutics Inc
    VivaCell Biotechnology Espana SL
    Voyager Therapeutics Inc
    vTv Therapeutics Inc
    Wellstat Therapeutics Corp

    Request for Sample

    Report Url https://www.reportsweb.com//parkinsons-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//parkinsons-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//parkinsons-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments